What does Neuromedics do?

Neuromedics is registered with the CBE as active in: Activiteiten van holdings. Private Limited, started on 25 November 2014, 1 establishment.

What is the address of Neuromedics?

The registered office of Neuromedics is located at Bredaseweg 20, 2322 Hoogstraten.

Is Neuromedics still active?

Yes. According to the CBE (16 September 2026) Neuromedics is active, legal situation “Normale toestand”, started on 25 November 2014.

Is Neuromedics registered on Peppol?

Yes, Neuromedics is registered on the Peppol network with ID 0208:0505687724.

What is the enterprise number of Neuromedics?

The enterprise number of Neuromedics is BE0505687724.

When was Neuromedics founded?

Neuromedics was founded on 25 November 2014.

Who are the directors of Neuromedics?

According to the 2025 annual accounts, the directors of Neuromedics are: Paul Richard Depauw.

Is Neuromedics a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 25 November 2014; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Neuromedics make in 2025?

Neuromedics posted a profit after taxes of € 88,858 in financial year 2025.

What is the revenue of Neuromedics?

As a small company, Neuromedics is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € -22,827.

Neuromedics (Private Limited) - Hoogstraten

Dossier Neuromedics, printed on 16 September 2026 from databakkes.be/en/0505687724/neuromedics. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Neuromedics from Hoogstraten, company number BE0505687724, closed financial year 2025 with a result of € 88,858 after tax. For that financial year Neuromedics recorded a gross margin of € -22,827 and equity of € 200,816. Compared with financial year 2024, the result moved from € 56,961 to € 88,858. Profitable, and profit is growing. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 10, 2026.

What it is worth Healthy

€ 200,816

▼ 33% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 88,858

▲ 56% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 70,913

▼ 16% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 188,858 paid out

More than the year’s profit went to the shareholders; reserves fell.

People and assets in 2025

Full-time equivalents estimate The annual accounts report no full-time equivalents. A micro company with one active director is usually run by that person; this is an assumption, not a figure from the source.

≈ 1

No payroll staff. One director, so that person most likely runs the business.

Vehicles and equipment

€ 32,997

▼ 30% vs 2024

Of which on lease € 31,988.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 33,748

▼ 27% vs 2024

€ 12,779 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 1,199

▲ € 998 vs 2024

Supplier invoices still open on the last day of the fiscal year.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 626 Gross margin 2022: € 626 First fiscal year in the series	€ -23,968 Gross margin 2023: € -23,968 ▼ € 24,594 vs 2022 (€ 626) Unfavourable step	€ -27,482 Gross margin 2024: € -27,482 ▼ € 3,514 vs 2023 (€ -23,968) Unfavourable step	€ -22,827 Gross margin 2025: € -22,827 ▲ € 4,655 vs 2024 (€ -27,482) Favourable step	▲ € 4,655
Profit after taxes	€ 98,710 Profit after taxes 2022: € 98,710 First fiscal year in the series	€ 90,805 Profit after taxes 2023: € 90,805 ▼ 8% vs 2022 (€ 98,710) Unfavourable step	€ 56,961 Profit after taxes 2024: € 56,961 ▼ 37% vs 2023 (€ 90,805) Unfavourable step	€ 88,858 Profit after taxes 2025: € 88,858 ▲ 56% vs 2024 (€ 56,961) Favourable step	▲ 56%
Equity	€ 243,856 Equity 2022: € 243,856 First fiscal year in the series	€ 243,856 Equity 2023: € 243,856 Unchanged (€ 243,856) Unchanged	€ 300,816 Equity 2024: € 300,816 ▲ 23% vs 2023 (€ 243,856) Favourable step	€ 200,816 Equity 2025: € 200,816 ▼ 33% vs 2024 (€ 300,816) Unfavourable step	▼ 33%
Total debts	€ 99,868 Total debts 2022: € 99,868 First fiscal year in the series	€ 150,321 Total debts 2023: € 150,321 ▲ 51% vs 2022 (€ 99,868) Unfavourable step	€ 46,917 Total debts 2024: € 46,917 ▼ 69% vs 2023 (€ 150,321) Favourable step	€ 124,371 Total debts 2025: € 124,371 ▲ 165% vs 2024 (€ 46,917) Unfavourable step	▲ 165%
Cash	€ 119,855 Cash 2022: € 119,855 First fiscal year in the series	€ 107,662 Cash 2023: € 107,662 ▼ 10% vs 2022 (€ 119,855) Unfavourable step	€ 83,984 Cash 2024: € 83,984 ▼ 22% vs 2023 (€ 107,662) Unfavourable step	€ 70,913 Cash 2025: € 70,913 ▼ 16% vs 2024 (€ 83,984) Unfavourable step	▼ 16%
Land & buildings	€ 562 Land & buildings 2022: € 562 First fiscal year in the series	-	-	-
Retained profit	€ 225,256 Retained profit 2022: € 225,256 First fiscal year in the series	€ 225,256 Retained profit 2023: € 225,256 Unchanged (€ 225,256) Unchanged	€ 282,216 Retained profit 2024: € 282,216 ▲ 25% vs 2023 (€ 225,256) Favourable step	€ 182,216 Retained profit 2025: € 182,216 ▼ 35% vs 2024 (€ 282,216) Unfavourable step	▼ 35%
Dividend	€ 98,710 Dividend 2022: € 98,710 First fiscal year in the series	€ 90,805 Dividend 2023: € 90,805 ▼ 8% vs 2022 (€ 98,710) Unchanged	€ 0 Dividend 2024: € 0 ▼ 100% vs 2023 (€ 90,805) Unchanged	€ 188,858 Dividend 2025: € 188,858 Unchanged (€ 0) Unchanged
Bank debt	€ 503 Bank debt 2022: € 503 First fiscal year in the series	€ 58,931 Bank debt 2023: € 58,931 ▲ € 58,428 vs 2022 (€ 503) Unfavourable step	€ 46,402 Bank debt 2024: € 46,402 ▼ 21% vs 2023 (€ 58,931) Favourable step	€ 33,748 Bank debt 2025: € 33,748 ▼ 27% vs 2024 (€ 46,402) Favourable step	▼ 27%
Balance sheet total	€ 343,724 Balance sheet total 2022: € 343,724 First fiscal year in the series	€ 394,176 Balance sheet total 2023: € 394,176 ▲ 15% vs 2022 (€ 343,724) Unchanged	€ 347,733 Balance sheet total 2024: € 347,733 ▼ 12% vs 2023 (€ 394,176) Unchanged	€ 325,187 Balance sheet total 2025: € 325,187 ▼ 6% vs 2024 (€ 347,733) Unchanged	▼ 6%

Key figures of Neuromedics, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Neuromedics?

What happened at Neuromedics in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 10, 2026 New annual accounts for financial year 2025: profit of € 88,858 (▲ 56% vs 2024). Source: NBB ↗
Nov 25, 2014 New establishment in Hoogstraten. KBO
Nov 25, 2014 Start of the company according to the CBE. KBO

In short

From € 98,710 profit in 2022 to € 88,858 profit in 2025.

Paid € 954 in corporate taxes since 2022.

Best year ever: 2022, with € 98,710 profit.

Paid out € 378,373 in dividends to the owners in total.

Original PDFs at the National Bank ↗

A new publication or filing at Neuromedics? We notify you, reason included.

Follow Neuromedics

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

Paul Richard Depauw

Neuromedics

Neuromedics 100%

Ergotrics 18.5%

Rewire 10.3%

Behind Neuromedics is Paul Richard Depauw. It owns 100% of Neuromedics, 18.5% of Ergotrics and 10.3% of Rewire itself.

See the full network in the app

Directors

According to the 2025 annual accounts

Paul Richard Depauw

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Bredaseweg 20

2322 Hoogstraten

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 3 companies are registered at this address.

All companies at this address →

ARTUCO

WIJNDOMEIN HOOGSTRATEN

€ -5,611 gross margin · 2025

ILDP

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0505.687.724

VAT number

BE 0505.687.724

Registered office

Bredaseweg 20, 2322 Hoogstraten

Names & denominations

Neuromedics

Enterprise type

Rechtspersoon

Legal form

Private limited company

Legal situation

Normale toestand

Start date

25 November 2014

Peppol

Active · Active since 23 Dec 2025

Activities · NACE

Activiteiten van holdings

Holdings

View on CBE Public ↗ Annual accounts (NBB) ↗

Neuromedics

Financials

What happened to Neuromedics?

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions